(LULU, ARNA, MTSN) CRWENewswire Stocks In Action Arena Pharmaceuticals Inc - ARNA - and Eisai Inc. reported that the FDA has accepted for filing and review Arena’s resubmission of the New Drug Application for lorcaserin. For the fourth quarter of fiscal 2011, Lululemon Athletica Inc - LULU - now expects diluted earnings per share to be in the range of $0.47 to $0.49 as compared to its previous guidance range for diluted earnings per share of $0.40 to $0.42